RaySearch Laboratories AB (0GRZ) AI Stock Analysis
RaySearch Laboratories AB
(LSE:0GRZ)
No summary available
RaySearch Laboratories AB (0GRZ) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- SEK 602.69M
- Dividend Yield
- 1.60%
- Average Volume (3M)
- 21.27K
- Price to Earnings (P/E)
- 31.7
- Beta (1Y)
- 0.74
- Revenue Growth
- 1.42%
- EPS Growth
- 10.40%
- Country
- UK
- Employees
- 464
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
RaySearch Laboratories AB Business Overview & Revenue Model
Company Description
RaySearch Laboratories AB (publ) is a global medical technology company dedicated to developing cutting-edge software solutions for cancer treatment. Its principal offering, RayStation, is a sophisticated treatment planning system that supports a vas...
RaySearch Laboratories AB Earnings Call Summary
The call was predominantly positive, supported by record Q3 sales, strong order intake, U.S. momentum, strategic customer wins, expanding RayCare adoption, substantial backlog and strong financial flexibility. However, license sales declined, margins were pressured by an unusually high hardware mix, free cash flow was negative, RayCare deal conversion remains gradual, reimbursement-related delays persist, and the full-year EBIT target requires an exceptionally strong fourth quarter.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
RaySearch expects growth to continue for the full year of 2026 and also expects a very strong end of 2026, with Q4 traditionally its strongest quarter; management said it will be “a stellar Q4” to achieve the full year EBIT margin target of at least 25%, which “remains within reach,” is “not a given” but “reasonable,” and excludes costs related to the long-term incentive program introduced in the second quarter this year. Management expects a few more RayCare orders this year, said RayCare will contribute in 2027, expects customer receivables to remain at the same high numbers in the next quarter but not increase further, and expects sales and marketing costs to be on about the same level in the next quarter as in this.
RaySearch Laboratories AB Peers Comparison
Overall Rating
SE:SECT.B74Outperform
SE:SUS69Neutral
SE:PAX60Neutral
SE:MNTC58Neutral
SE:CRAD.B56Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:SECT.B | 74Outperform | SEK 67.51B | 101.10 | 30.26% | 0.38% | 13.94% | 5.70% |
| SE:SUS | 69Neutral | SEK 3.00B | 32.21 | ― | ― | 8.40% | 0.74% |
| SE:PAX | 60Neutral | SEK 1.54B | -292.39 | -1.22% | ― | 34.05% | -144.96% |
| SE:MNTC | 58Neutral | SEK 435.95M | -91.65 | -3.61% | ― | 15.87% | 92.43% |
| SE:CRAD.B | 56Neutral | SEK 783.39M | 16.70 | 13.23% | 0.43% | -8.76% | 103.87% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0GRZ | RaySearch Laboratories AB Class B | 196.50 | -20.04 | -9.25% | |
| SE:PAX | Paxman AB | 63.80 | -2.40 | -3.63% | |
| SE:CRAD.B | C-Rad AB Class B | 23.50 | -9.40 | -28.57% | |
| SE:SECT.B | Sectra AB Class B | 330.60 | 36.35 | 12.35% | |
| SE:MNTC | Mentice AB | 15.70 | 6.30 | 67.02% | |
| SE:SUS | Surgical Science Sweden AB | 58.95 | -24.45 | -29.32% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.